{"id":37157,"date":"2026-03-07T15:04:53","date_gmt":"2026-03-07T20:04:53","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=37157"},"modified":"2026-03-07T15:04:54","modified_gmt":"2026-03-07T20:04:54","slug":"sell-granulation-systems-before-the-drug-patent-expires-how-biopharma-equipment-suppliers-can-turn-drug-loe-timelines-into-a-predictable-sales-pipeline","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/sell-granulation-systems-before-the-drug-patent-expires-how-biopharma-equipment-suppliers-can-turn-drug-loe-timelines-into-a-predictable-sales-pipeline\/","title":{"rendered":"Sell Granulation Systems Before the Drug Patent Expires: How Biopharma Equipment Suppliers Can Turn Drug LOE Timelines Into a Predictable Sales Pipeline"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

There is a predictable moment in generic drug manufacturing when a company’s capital expenditure committee approves a granulation line that has been sitting in proposal review for eight months. That moment is not random. It occurs roughly 18 to 24 months before a target drug’s first possible generic entry date, when the commercial case for the manufacturing investment finally clears the internal IRR threshold.<\/p>\n\n\n\n

Equipment suppliers who understand that timing can build a sales pipeline with more forward visibility than almost any other capital goods market. The ones who ignore it will keep responding to RFPs they did not see coming, competing on price against three other vendors, and wondering why their close rates are declining.<\/p>\n\n\n\n

Granulation systems sit at the center of this opportunity. Wet granulation, dry granulation, and fluid bed granulation are the dominant intermediate processing steps for the vast majority of oral solid dose generics. When a blockbuster drug approaches loss of exclusivity (LOE) and the generic development pipeline activates, granulation equipment orders follow. The correlation is not coincidental. It is structural.<\/p>\n\n\n\n

This article is for the business development, sales, and marketing leaders at granulation equipment suppliers who want to convert that structural correlation into a deliberate, documented commercial strategy.<\/p>\n\n\n\n

\n\n\n\n

Why Granulation Is the Right Equipment Category to LOE-Align<\/strong><\/h2>\n\n\n\n

Before addressing the strategy, the technical case for granulation’s LOE relevance deserves a direct explanation.<\/p>\n\n\n\n

Oral solid dose drugs, specifically tablets and capsules, represent approximately 60% of all generic drug volume in the U.S. [1]. The vast majority of these products require granulation as an intermediate step in manufacturing, either to improve powder flowability, enhance compressibility, control drug release, or achieve blend uniformity that direct compression cannot reliably deliver.<\/p>\n\n\n\n

High-potency active pharmaceutical ingredients (APIs), modified-release formulations, and combination products, all of which are disproportionately represented in the blockbuster drug LOE pipeline, typically require more complex granulation processes than commodity generics. A generic manufacturer preparing to produce a modified-release metformin-sitagliptin combination after patent expiration cannot simply transfer a legacy granulation process from another product. They need equipment validated for that specific formulation’s processing requirements.<\/p>\n\n\n\n

When a patent cliff approaches for a high-revenue branded oral solid dose drug, multiple generic manufacturers file Paragraph IV certifications asserting the right to early market entry. Each of those manufacturers needs to validate a manufacturing process. Many of them need capital equipment. The granulation systems market does not drive this demand; the LOE calendar creates it.<\/p>\n\n\n\n

The supplier’s job is to know the LOE calendar before their customers’ capital committees do.<\/p>\n\n\n\n

\n\n\n\n

The LOE Calendar Is Public. Most Equipment Suppliers Don’t Use It.<\/strong><\/h2>\n\n\n\n

Patent expiration data for branded pharmaceuticals is available in the FDA’s Orange Book, which lists the patents and regulatory exclusivities associated with every approved new drug application. For biosimilars and biologics, the Purple Book tracks reference biologic exclusivity. Both databases are public, regularly updated, and machine-readable.<\/p>\n\n\n\n

DrugPatentWatch aggregates this data, adds Paragraph IV certification filings, litigation histories, and authorized generic intelligence, and presents it in a format that is commercially actionable for anyone willing to use it [2]. For an equipment supplier’s business development team, the platform provides answers to the first-order commercial question: which drugs, in which therapeutic classes, are approaching LOE in the next 12 to 48 months, and who has already signaled intent to enter the generic market?<\/p>\n\n\n\n

Paragraph IV filings are the most actionable data point in this stack. When a generic manufacturer files a Paragraph IV certification asserting patent invalidity or non-infringement against a specific brand, they are registering commercial intent. That filing is publicly disclosed through litigation records, and DrugPatentWatch tracks active certifications in near real time [2]. A granulation supplier who monitors Paragraph IV filings for oral solid dose drugs can identify which generic manufacturers are actively developing which products before those manufacturers have publicly announced their pipeline.<\/p>\n\n\n\n

That intelligence, translated into account targeting, means the equipment supplier is calling on the process engineering team at the generic manufacturer while the development project is still in early-stage feasibility, before the RFP is written.<\/p>\n\n\n\n

The standard equipment sales process, where the supplier waits for an RFP to arrive and then competes in a structured evaluation, is a structural disadvantage. By the time an RFP for a granulation line is issued, the buyer has already decided the primary technical specification and often has a preferred vendor in mind. The RFP is frequently a procurement compliance exercise. Suppliers who enter at the RFP stage are competing to lose gracefully.<\/p>\n\n\n\n

\n\n\n\n

How Generic Drug Development Timelines Create Equipment Demand Signals<\/strong><\/h2>\n\n\n\n

Understanding exactly when granulation equipment demand is generated requires a working knowledge of generic drug development timelines.<\/p>\n\n\n\n

After a Paragraph IV certification is filed, two scenarios play out. The branded manufacturer either sues for patent infringement, triggering a 30-month automatic stay on FDA approval of the generic, or does not sue, in which case the FDA can approve the generic upon completion of its review. In the 30-month stay scenario, the generic manufacturer has a relatively long window to complete process development and scale-up before commercial launch. In the no-suit scenario, the timeline compresses and equipment decisions become urgent.<\/p>\n\n\n\n

Process development for a complex oral solid dose generic typically requires 12 to 24 months from laboratory-scale work to validated commercial-scale manufacturing. This timeline includes formulation development, granulation process optimization, equipment qualification (IQ\/OQ\/PQ), and FDA process validation requirements under 21 CFR Part 211. For modified-release products, the timeline often extends toward the upper bound due to dissolution testing complexity.<\/p>\n\n\n\n

The capital expenditure decision for manufacturing equipment typically occurs at the point when the formulation has cleared proof-of-concept and the development team has demonstrated process feasibility at bench or pilot scale. That decision point usually falls 18 to 30 months before the expected commercial launch date.<\/p>\n\n\n\n

Mapping backward from expected LOE dates, a granulation equipment supplier can identify the likely capital expenditure decision window for each major product in the generic development pipeline. For a drug with an expected LOE in Q1 2028 and a 30-month stay in effect from a patent lawsuit filed in early 2025, the effective commercial launch window opens in mid-2027, and the capital expenditure decision likely occurs in 2025 or 2026.<\/p>\n\n\n\n

That decision point is now. An equipment supplier reading this can check the current Paragraph IV filing calendar on DrugPatentWatch and identify which product programs at which generic manufacturers are in the capital expenditure window right now.<\/p>\n\n\n\n

\n\n\n\n

Profiling the Target: Which Generic Manufacturers Are Your Buyers?<\/strong><\/h2>\n\n\n\n

The generic pharmaceutical manufacturing market in the U.S. is concentrated at the top and fragmented at the middle. The largest generic manufacturers by revenue, companies like Teva, Viatris, Sandoz, Amneal, and Sun Pharma, have internal manufacturing capacity and sophisticated capital planning processes. Mid-tier generic manufacturers have less internal capacity and are more likely to be making greenfield or brownfield equipment investments tied to specific product launches.<\/p>\n\n\n\n

For granulation equipment suppliers, the mid-tier segment is frequently the highest-margin opportunity. Large manufacturers have procurement leverage, standardized vendor lists, and price sensitivity that makes complex equipment selling difficult. Mid-tier manufacturers are making one or two major capital investments per year, often tied to a specific LOE target, and they are more likely to pay for technical differentiation if it reduces their development timeline or improves their process validation success rate.<\/p>\n\n\n\n

The target account profile for LOE-aligned granulation marketing looks like this: a generic manufacturer with annual revenues between $200 million and $2 billion that has filed one or more Paragraph IV certifications against branded oral solid dose drugs with LOE windows in the next 24 to 36 months. That manufacturer has an active ANDA pipeline, a process development team that is currently making formulation decisions, and a capital expenditure cycle that will open in the next 6 to 18 months.<\/p>\n\n\n\n

Identifying these companies does not require proprietary intelligence. Paragraph IV certifications are disclosed in litigation records and tracked by DrugPatentWatch. ANDA filings with the FDA are partially public, with application numbers disclosed during the patent certification process. Annual reports and investor presentations from publicly traded generic manufacturers often describe product pipeline priorities without naming the specific drug being developed.<\/p>\n\n\n\n

A business development analyst at a granulation equipment supplier who spends four hours per week monitoring Paragraph IV filings and cross-referencing them with the company’s existing account relationships can produce a prioritized target account list that their direct competitors are not using.<\/p>\n\n\n\n

\n\n\n\n

The Technical Alignment Problem<\/strong><\/h2>\n\n\n\n

LOE-aligned marketing is not only a business development exercise. It requires genuine technical alignment between the granulation equipment offered and the processing requirements of the drugs approaching LOE.<\/p>\n\n\n\n

Different drug classes and formulation types require fundamentally different granulation approaches. Wet granulation with high-shear mixers is the standard process for many immediate-release solid dose products. Fluid bed granulation is preferred for moisture-sensitive APIs and for products where particle size distribution control is critical. Dry granulation via roller compaction is used for APIs that degrade under heat or moisture conditions typical of wet processes. Continuous granulation systems, which process material in a continuous flow rather than batch mode, are gaining adoption for high-volume products where batch size variability creates regulatory risk.<\/p>\n\n\n\n

When a specific drug approaches LOE, the granulation process requirements are largely determinable from the drug’s physicochemical properties and its approved dosage form. A modified-release tablet with a matrix-controlled release mechanism will require a granulation process capable of producing consistent particle size distribution and controlled porosity. An immediate-release combination tablet with two APIs of different solubility profiles will require a granulation approach that achieves content uniformity without creating a dissolution differential between the two APIs.<\/p>\n\n\n\n

Granulation equipment suppliers who analyze the formulation type of drugs approaching LOE can pre-position the specific technical capabilities of their systems against those requirements. The sales conversation shifts from “here is our granulator” to “here is how our system addresses the specific challenge of scaling the modified-release granulation process for a drug with these API properties.”<\/p>\n\n\n\n

That level of technical specificity is not difficult to achieve for a company that builds granulation equipment. The API properties and formulation type of any approved drug are partially available through published literature, patent claims in the drug’s patent estate, and FDA drug product characterization data in the product’s NDA. The work required is to systematically analyze upcoming LOE drugs against these technical parameters and match them to the supplier’s product capabilities.<\/p>\n\n\n\n

\n\n\n\n

Case Study: The Extended-Release Metformin Opportunity<\/strong><\/h2>\n\n\n\n

Metformin extended-release products, specifically combination fixed-dose products containing metformin with DPP-4 inhibitors and SGLT-2 inhibitors, represent one of the most technically demanding granulation challenges in the oral solid dose generic space. Several of these combinations have experienced LOE events or are approaching them between 2023 and 2027.<\/p>\n\n\n\n

The granulation challenge for these products is not the metformin itself, which is a well-understood compound with established manufacturing processes. The challenge is achieving uniform blend and consistent dissolution performance for the lower-dose API component, which must maintain its release profile in the presence of the large metformin granule mass.<\/p>\n\n\n\n

Fluid bed granulation and controlled agglomeration approaches have been explored in the patent literature for these formulations. Equipment suppliers who have developed fluid bed systems with process analytical technology (PAT) integration for real-time particle size monitoring are better positioned to win development contracts for these products than suppliers offering standard batch wet granulation without PAT capability.<\/p>\n\n\n\n

The market opportunity is substantial. Combined U.S. sales for metformin combination products that have experienced or are approaching LOE exceeded $5 billion at peak branded revenue [3]. Even capturing a fraction of the equipment investment required by the generic manufacturers developing these products represents a meaningful revenue opportunity for a granulation equipment supplier who has pre-positioned technically.<\/p>\n\n\n\n

The lesson generalizes: for any high-revenue oral solid dose drug approaching LOE, the granulation challenge is technically specifiable in advance, and the equipment supplier who has matched their capability to that challenge before the RFP is written has a structural sales advantage.<\/p>\n\n\n\n

\n\n\n\n

The Content Marketing Funnel for LOE-Aligned Equipment Selling<\/strong><\/h2>\n\n\n\n

Technical pre-positioning needs a distribution mechanism. The process engineers and formulation scientists making granulation equipment recommendations at generic manufacturers do not read trade advertising. They read application notes, white papers, technical conference proceedings, and peer-reviewed literature. They attend AAPS, Interphex, ACHEMA, and CPhI. They follow LinkedIn content from people who demonstrate genuine technical understanding of pharmaceutical manufacturing processes.<\/p>\n\n\n\n

A granulation equipment supplier that publishes specific technical content aligned to upcoming LOE events is doing something that its competitors almost universally do not do. The content formula is straightforward: identify a drug approaching LOE, analyze the granulation processing challenge for the generic version of that drug, and publish a technical analysis of how that challenge can be addressed using the company’s equipment capability.<\/p>\n\n\n\n

The title of that piece of content should not be “Our Fluid Bed Granulator Handles Modified Release Products.” It should be something like: “Granulation Scale-Up Strategies for Metformin Combination Generics: Managing Content Uniformity at Pilot and Commercial Scale.” That title attracts the specific process engineer who is working on that exact problem. They find it through a Google search or a LinkedIn recommendation. They read it. They contact the supplier.<\/p>\n\n\n\n

This approach is hyper-targeted because the audience is hyper-targeted. There are maybe 200 to 400 process engineers and formulation scientists in the U.S. who are actively working on granulation process development for any given major oral solid dose generic program. Reaching all of them with a technically credible piece of content costs almost nothing relative to the equipment sale value. <blockquote> “The U.S. generic pharmaceutical market is projected to reach $115 billion by 2027, with oral solid dose products continuing to represent the largest volume segment and driving the majority of new manufacturing investment.” [4] <\/blockquote><\/p>\n\n\n\n

The content strategy should be organized around a 12-month rolling LOE calendar. Each quarter, the marketing team identifies the two or three most technically significant oral solid dose drugs approaching LOE in the 18 to 36-month window, analyzes their formulation requirements, and produces technical content aligned to those requirements. The sales team uses that content as a pre-call research and conversation tool when targeting the generic manufacturers who have filed Paragraph IV certifications against those drugs.<\/p>\n\n\n\n

\n\n\n\n

Trade Show Strategy: From Booth to Briefing<\/strong><\/h2>\n\n\n\n

Pharmaceutical equipment trade shows are an expensive, underutilized asset for most granulation equipment suppliers. The standard trade show posture is to build a booth demonstrating equipment capabilities generically and wait for visitors to self-select. This produces a stream of low-intent visitors, one or two qualified leads, and a cost-per-lead figure that is hard to justify.<\/p>\n\n\n\n

An LOE-aligned trade show strategy looks different. Before each major trade show, the business development team identifies the generic manufacturers who will be attending and who have active development programs for drugs in the LOE window. For each of those companies, the team prepares a brief on the specific granulation challenge relevant to their program and reaches out in advance to request a specific meeting during the show.<\/p>\n\n\n\n

The meeting invitation is not a sales pitch. It is a request to discuss a technical problem the prospect is known to be working on. “We have been doing analysis on granulation approaches for modified-release diabetes combination products and have some process data we think would be relevant to your development program. Can we schedule 30 minutes at Interphex?” That invitation has a higher acceptance rate than “We would love to show you our new granulation platform.”<\/p>\n\n\n\n

This approach requires the pre-show preparation to be genuine. The technical analysis needs to exist. The process data needs to be real. The discussion needs to be a peer technical conversation, not a product demonstration disguised as a consultation. The generic manufacturer’s process engineers will know the difference immediately.<\/p>\n\n\n\n

The LOE intelligence layer makes this possible. Without knowing which drugs a specific generic manufacturer is developing, you cannot have a targeted technical conversation. With Paragraph IV filing data from DrugPatentWatch and a working knowledge of the granulation challenges associated with specific drug formulations, you can walk into that trade show with a prospect-specific brief for each meeting on your calendar [2].<\/p>\n\n\n\n

\n\n\n\n

Continuous Manufacturing: The LOE-Driven Adoption Catalyst<\/strong><\/h2>\n\n\n\n

Continuous granulation represents a shift in pharmaceutical manufacturing that is accelerating partly because of the LOE pipeline itself.<\/p>\n\n\n\n

FDA has been actively encouraging continuous manufacturing adoption through its guidance documents and through the Emerging Technology Program, which provides early interaction with FDA on manufacturing innovation before NDA or ANDA submission [5]. The regulatory pathway for continuous manufacturing ANDAs is now sufficiently established that risk-averse generic manufacturers are no longer treating it as experimental.<\/p>\n\n\n\n

The economic case for continuous granulation over batch granulation becomes compelling at commercial scale for high-volume products. Reduced equipment footprint, lower material inventory, improved process control, and faster response to out-of-specification events are all documented advantages. For a generic manufacturer planning commercial production of a high-volume oral solid dose drug, the capital investment calculation for continuous versus batch granulation is not straightforward, but for products requiring more than 50,000 to 100,000 kilograms of annual production, continuous systems frequently win on 10-year NPV.<\/p>\n\n\n\n

Several of the most significant oral solid dose drugs approaching LOE in the 2025 to 2029 window are high-volume products in large patient populations: diabetes drugs, cardiovascular drugs, respiratory products. For each of these products, at least one or two generic manufacturers with scale ambitions will evaluate continuous manufacturing as part of their technology selection.<\/p>\n\n\n\n

Granulation equipment suppliers with continuous manufacturing capability who align their marketing with the high-volume LOE drugs approaching in this window are addressing a buyer who is making both a technology decision and a capital decision simultaneously. The sale is more complex than a batch granulator installation, but the contract value is significantly higher and the competitive field is narrower.<\/p>\n\n\n\n

\n\n\n\n

Regulatory Intelligence as Sales Enablement<\/strong><\/h2>\n\n\n\n

The granulation equipment sale does not end at equipment delivery. The generic manufacturer needs to validate the equipment and include the manufacturing process in its ANDA submission. That validation process is defined by FDA’s process validation guidance and by the equipment-specific requirements in 21 CFR Part 211. For continuous manufacturing, the process validation expectations include demonstrated process control across the full operational design space.<\/p>\n\n\n\n

Granulation equipment suppliers who provide comprehensive validation documentation packages, including IQ\/OQ protocols, calibration procedures, and process capability data generated on equivalent systems, are removing a significant friction point from the buyer’s timeline. Every day a generic manufacturer’s manufacturing line is not validated is a day their ANDA cannot be approved and commercial launch cannot proceed.<\/p>\n\n\n\n

The LOE calendar creates a time pressure that makes this friction point measurable in dollars. If a drug has an expected generic entry date in April 2027 and the generic manufacturer needs 12 months of validated commercial production data to support their ANDA, their equipment validation window closes in early 2026. A granulation equipment supplier who can commit to a validation documentation package that shortens the qualification timeline by 60 days is offering a quantifiable commercial benefit.<\/p>\n\n\n\n

Most equipment suppliers can estimate the revenue value of 60 days of commercial production for a first-to-file generic entrant. It is often in the range of $10 million to $50 million for a major branded drug’s generic. Framing validation support in those terms converts a technical service discussion into a financial ROI conversation.<\/p>\n\n\n\n

The regulatory intelligence required to make this argument credibly is not exotic. It requires knowing the FDA’s current expectations for process validation documentation for the specific equipment type, understanding the ANDA review timeline for the drug in question (which is visible through FDA’s published GDUFA II goals and current review backlogs), and being able to map the equipment qualification timeline against the ANDA submission deadline.<\/p>\n\n\n\n

\n\n\n\n

Pricing and Contract Structures for LOE-Aligned Sales<\/strong><\/h2>\n\n\n\n

Equipment contracts aligned to LOE development programs have different pricing and structuring considerations than standard capital equipment sales.<\/p>\n\n\n\n

The generic manufacturer’s willingness to pay for granulation equipment is a function of their confidence in eventual market entry. A company with a first-filer 180-day exclusivity position on a $500 million drug has a very different equipment investment calculus than a company that is the fifth Paragraph IV filer on the same drug with uncertain commercial prospects. The equipment supplier who understands that distinction can structure proposals accordingly.<\/p>\n\n\n\n

For first-filer or early-filer generic manufacturers with high confidence in market entry, the equipment investment is effectively a revenue-generating asset with a calculable payback period. A $3 million granulation line that enables commercial production of a generic drug generating $50 million in annual revenue pays back in weeks. In that context, price negotiation should be minimal and the supplier’s value proposition should focus entirely on timeline and technical capability.<\/p>\n\n\n\n

For later-filers or manufacturers with more uncertain market entry prospects, the equipment investment carries more risk. Here, leasing or deferred payment structures tied to ANDA approval milestones reduce the buyer’s capital commitment and remove a barrier to sale. Several pharmaceutical equipment finance companies offer ANDA-contingent leasing structures that allow generic manufacturers to take equipment delivery without full capital commitment before FDA approval [6]. Equipment suppliers who have established relationships with these finance partners and who can present financing options as part of the equipment proposal are removing a significant objection.<\/p>\n\n\n\n

The risk for the equipment supplier in milestone-contingent contracts is real but manageable. The mitigation is to focus these structures on first-filer or authorized generic developers where the probability of market entry is high, and to avoid them for later-filer programs where the commercial case is weak.<\/p>\n\n\n\n

\n\n\n\n

Account Segmentation for LOE-Aligned Granulation Marketing<\/strong><\/h2>\n\n\n\n

A practical account segmentation model for granulation equipment suppliers aligned to LOE events organizes target accounts across two axes: proximity to LOE decision window and technical match to the supplier’s granulation capability.<\/p>\n\n\n\n

The highest-priority segment is accounts where the decision window is open (capital expenditure decision likely within 12 months) and the technical match is strong (the drug’s formulation type maps to the supplier’s demonstrated capability). These accounts get dedicated business development attention, pre-call technical research, and executive relationship investment.<\/p>\n\n\n\n

The second segment is accounts where the decision window is 12 to 24 months out and the technical match is strong. These accounts receive content marketing, technical engagement at trade shows, and relationship-building with process development teams. The goal is to be the supplier with the established relationship and the relevant technical track record when the capital decision opens.<\/p>\n\n\n\n

The third segment is accounts where the technical match is weak regardless of timing. These accounts require either a genuine capability expansion or a referral to a better-matched competitor. Pursuing them wastes sales resources and produces contracts the supplier cannot execute well.<\/p>\n\n\n\n

The fourth segment is accounts where the LOE timing is beyond 24 months but the technical match is strong. These accounts are candidates for early-stage technical collaboration, potentially including collaborative process development work on scale-up challenges, which both advances the relationship and generates technical data for future content marketing.<\/p>\n\n\n\n

This segmentation model requires the business development team to maintain a current LOE intelligence database. The investment is modest. A dedicated analyst reviewing DrugPatentWatch quarterly updates, cross-referencing new Paragraph IV filings against the company’s account list, and categorizing accounts by their position in the segmentation matrix can maintain this system with approximately two to four hours of work per week.<\/p>\n\n\n\n

\n\n\n\n

The International LOE Opportunity<\/strong><\/h2>\n\n\n\n

Drug patent expiration is not exclusively a U.S. market event. Branded drugs lose exclusivity in the EU, Japan, China, and other major pharmaceutical markets on schedules that are partially, but not entirely, aligned with U.S. LOE dates. European patent expiration timelines follow the EU’s Supplementary Protection Certificate (SPC) system, which can extend effective exclusivity beyond the base patent term by up to five years [7].<\/p>\n\n\n\n

Generic manufacturers in India, China, and Eastern Europe preparing to enter European or regulated markets upon LOE often need to upgrade their manufacturing infrastructure to meet EMA Good Manufacturing Practice (GMP) standards. Granulation equipment suppliers with GMP-compliant systems and experience navigating EMA equipment qualification requirements have an addressable market in these manufacturers that mirrors the U.S. opportunity.<\/p>\n\n\n\n

The challenge in international markets is intelligence quality. Patent expiration timelines in the EU are tracked less systematically than in the U.S., and the equivalent of DrugPatentWatch for European patent data is less comprehensive. However, European patent expiration data is available through the European Patent Office’s Espacenet database, and several pharmaceutical patent analytics firms provide EU LOE intelligence that can be used to identify equipment investment triggers.<\/p>\n\n\n\n

For granulation equipment suppliers with European distribution or direct sales presence, building an EU-equivalent LOE monitoring capability is a tractable business development investment. The mechanics are the same as in the U.S.: identify drugs approaching LOE, identify the generic manufacturers preparing to enter, match the formulation requirements to the supplier’s technical capabilities, and engage before the RFP.<\/p>\n\n\n\n

\n\n\n\n

Measuring the ROI of LOE-Aligned Marketing<\/strong><\/h2>\n\n\n\n

Business development leaders who adopt LOE-aligned granulation marketing need to track its performance against conventional account-based marketing approaches. The relevant metrics are pipeline entry point (did the supplier engage before or after the RFP?), competitive position at deal close (sole source, preferred vendor, or competitive bid?), average contract value, and close rate by account segment.<\/p>\n\n\n\n

Pre-RFP engagement should produce higher close rates and higher contract values than post-RFP competitive bids. The differential is the measurable return on the LOE intelligence investment. If pre-RFP deals close at 60% and post-RFP deals close at 20%, and the average contract value is comparable, the LOE-aligned business development investment pays for itself if it shifts 20% of pipeline opportunities from post-RFP to pre-RFP status.<\/p>\n\n\n\n

At a typical granulation system contract value of $500,000 to $5 million, the revenue impact of that shift is large relative to the cost of maintaining an LOE intelligence capability. The analyst time, the DrugPatentWatch subscription, and the incremental technical content production cost are modest fractions of a single incremental contract win.<\/p>\n\n\n\n

The tracking infrastructure required is a CRM system with fields for LOE intelligence data: the target drug, the expected LOE date, the generic manufacturer’s Paragraph IV filing date, and the date of first supplier engagement relative to those events. Most equipment sales organizations do not track these fields today. Adding them to the CRM and reviewing them in quarterly pipeline meetings is a straightforward operational change.<\/p>\n\n\n\n

\n\n\n\n

The Supplier Who Calls First, Wins Most<\/strong><\/h2>\n\n\n\n

The fundamental commercial insight in LOE-aligned granulation equipment marketing is that the equipment buying decision is not made at the moment the RFP is issued. It is made progressively over the course of a development program, starting from the first time a process engineer begins thinking seriously about commercial-scale manufacturing.<\/p>\n\n\n\n

Suppliers who are present in that early thinking, who have established technical credibility on the specific challenge the development team is facing, and who have demonstrated knowledge of the development program’s commercial context are not just vendors. They are development partners. That status is earned by showing up early with useful technical knowledge, not by having the lowest price in a competitive bid.<\/p>\n\n\n\n

The LOE calendar is the most reliable forward signal of pharmaceutical equipment demand that exists. It is public, it is structured, and it is largely ignored by the granulation equipment industry in favor of reactive sales processes.<\/p>\n\n\n\n

The suppliers who build a systematic capability to read that calendar, match its technical implications to their product strengths, and engage target accounts before the capital decision window opens will consistently outperform competitors who wait for the phone to ring. The calendar does not lie. The only question is whether you are looking at it.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n

Drug patent expiration dates are public information that predicts granulation equipment demand with a lead time of 18 to 36 months. Most equipment suppliers do not use this information systematically. Those who do gain a structural pre-RFP engagement advantage that directly improves close rates and contract values.<\/p>\n\n\n\n

Paragraph IV certification filings, tracked through platforms like DrugPatentWatch, identify which generic manufacturers are developing which specific products before those development programs are publicly disclosed. This intelligence is the foundation of an effective account targeting strategy for equipment suppliers.<\/p>\n\n\n\n

Class-specific LOE analysis reveals the granulation process challenges associated with each drug approaching patent expiration. Matching those challenges to the supplier’s technical capabilities before the buyer’s RFP process begins is the mechanism by which LOE intelligence converts to sales pipeline.<\/p>\n\n\n\n

Content marketing aligned to specific upcoming LOE events reaches the process engineers and formulation scientists making equipment recommendations at the exact moment they are actively looking for technical guidance on the challenge the content addresses.<\/p>\n\n\n\n

The ROI case for LOE-aligned marketing is quantifiable. Pre-RFP engagement produces higher close rates and higher contract values than competitive RFP responses. The cost of maintaining an LOE monitoring capability is a small fraction of the incremental contract value generated by a single additional pre-RFP win.<\/p>\n\n\n\n

\n\n\n\n

Frequently Asked Questions<\/strong><\/h2>\n\n\n\n

Q1: How specific does an equipment supplier’s LOE intelligence need to be to be useful for sales targeting?<\/strong><\/p>\n\n\n\n

It needs to be specific enough to identify the development program, the likely buyer, and the approximate capital expenditure decision window. That means knowing the drug name, the expected LOE date, the Paragraph IV filers (which identifies the likely equipment buyers), and an assessment of the granulation process requirements based on the drug’s formulation type. You do not need clinical or commercial sales forecasts to prioritize a target account. You need to know that Company X has filed a Paragraph IV against Drug Y, that Drug Y is an extended-release tablet with known moisture sensitivity, and that Company X’s capital expenditure decision for the commercial line will likely open in the next 12 to 18 months given the LOE timeline. That level of specificity is achievable with publicly available data in under two hours of research per account.<\/p>\n\n\n\n

Q2: What is the risk that LOE-aligned intelligence leads to over-investment in accounts where generic entry is blocked by patent litigation outcomes?<\/strong><\/p>\n\n\n\n

It is real, and it is manageable with scenario analysis. The 30-month automatic stay triggered by a patent infringement lawsuit does not eliminate the generic entry opportunity; it delays it. In most cases, the generic manufacturer continues their development program during the stay, because if they win the litigation or if the patent is invalidated, they want to be ready to launch on day one of generic availability. Equipment investment decisions during the stay are driven by the manufacturer’s assessment of their litigation position, which is not publicly observable. The mitigation for the equipment supplier is to qualify the account’s litigation posture during the sales process and to understand whether the manufacturer is investing in commercial manufacturing capability or holding at pilot scale pending litigation resolution. That distinction is usually visible through the scale of the equipment discussion.<\/p>\n\n\n\n

Q3: How does continuous granulation technology change the LOE-aligned equipment selling strategy?<\/strong><\/p>\n\n\n\n

It adds a technology selection conversation on top of the capital investment conversation. When a generic manufacturer is evaluating continuous versus batch granulation for a high-volume LOE drug, the LOE timeline affects the technology decision: if the commercial launch date is 18 months away, there may not be enough time to qualify a continuous manufacturing system, and the buyer defaults to batch. If the launch date is 30 to 36 months out, continuous manufacturing is technically feasible and the economic case is worth building. Equipment suppliers with continuous manufacturing capability should segment their LOE target account list by launch timeline, reserving continuous manufacturing sales conversations for accounts with sufficient development runway, and focusing batch system selling on accounts with tighter timelines. The two conversations require different technical content, different financial ROI models, and different regulatory support packages.<\/p>\n\n\n\n

Q4: Can granulation equipment suppliers use LOE intelligence to develop private-label or contract manufacturing partnerships, not just equipment sales?<\/strong><\/p>\n\n\n\n

Yes, and this is an underutilized channel. Several granulation equipment manufacturers operate or have relationships with contract development and manufacturing organizations (CDMOs). When a generic manufacturer lacks internal manufacturing capacity and is evaluating both buying equipment and using a CDMO for initial commercial batches, the equipment supplier who has a CDMO partner can offer a hybrid solution: use the CDMO for the first year of commercial production while the manufacturer’s internal line is validated. This extends the supplier’s commercial relationship from the development phase through the launch phase and creates a long-term client who eventually purchases the commercial equipment. The LOE intelligence layer identifies which generic manufacturers are capacity-constrained by reviewing their public disclosures for manufacturing facility investments or lack thereof.<\/p>\n\n\n\n

Q5: How should granulation equipment suppliers handle competitors who also monitor the same LOE data and target the same accounts?<\/strong><\/p>\n\n\n\n

The LOE intelligence itself is not proprietary. What is proprietary is the supplier’s ability to convert that intelligence into a technically credible, account-specific engagement before the buyer’s decision is made. The competitive moat is not information access; it is the quality and speed of technical response. A supplier who calls on a generic manufacturer’s process engineering team with a formulation-specific granulation analysis six months before the RFP will beat a competitor who sends a generic product brochure after tracking the same Paragraph IV filing. The differentiation lives in execution quality, not data exclusivity. Suppliers who invest in building a technically capable business development function, one where the business development person can have a credible granulation process conversation, not just a sales conversation, will consistently outperform competitors who are working from the same data but applying it superficially.<\/p>\n\n\n\n

\n\n\n\n

Citations<\/strong><\/h2>\n\n\n\n

[1] IQVIA Institute for Human Data Science. (2024). The use of medicines in the U.S. 2024: Usage and spending trends and outlook to 2028<\/em>. IQVIA Institute.<\/p>\n\n\n\n

[2] DrugPatentWatch. (2025). Drug patent and exclusivity database including Paragraph IV certification tracking<\/em>. DrugPatentWatch. https:\/\/www.drugpatentwatch.com<\/p>\n\n\n\n

[3] U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations<\/em> (43rd ed.). FDA. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/<\/p>\n\n\n\n

[4] Grand View Research. (2024). U.S. generic drugs market size, share & trends analysis report, 2024-2030<\/em>. Grand View Research. https:\/\/www.grandviewresearch.com\/industry-analysis\/us-generic-drugs-market<\/p>\n\n\n\n

[5] U.S. Food and Drug Administration. (2019). Emerging technology program<\/em>. FDA. https:\/\/www.fda.gov\/drugs\/pharmaceutical-quality-resources\/emerging-technology-program<\/p>\n\n\n\n

[6] Cohn, R. A., & Steele, M. T. (2022). Financing structures for pharmaceutical manufacturing capital in the ANDA development cycle. Journal of Generic Medicines, 18<\/em>(3), 91-103. https:\/\/doi.org\/10.1177\/17411343221094551<\/p>\n\n\n\n

[7] European Patent Office. (2024). Supplementary protection certificates: A guide to SPCs in Europe<\/em>. EPO. https:\/\/www.epo.org\/en\/legal\/guide-epc\/2023\/a63.html<\/p>\n","protected":false},"excerpt":{"rendered":"

There is a predictable moment in generic drug manufacturing when a company’s capital expenditure committee approves a granulation line that […]<\/p>\n","protected":false},"author":1,"featured_media":37162,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-37157","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=37157"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37157\/revisions"}],"predecessor-version":[{"id":37163,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37157\/revisions\/37163"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/37162"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=37157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=37157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=37157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}